Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer

M. Skalickova, K. Hadrava Vanova, O. Uher, J. Leischner Fialova, K. Petrlakova, M. Masarik, Z. Kejík, P. Martasek, K. Pacak, M. Jakubek

. 2024 ; 15 (-) : 1479483. [pub] 20250109

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010292

Grantová podpora
Z01 HD008735 Intramural NIH HHS - United States

Despite enormous progress, advanced cancers are still one of the most serious medical problems in current society. Although various agents and therapeutic strategies with anticancer activity are known and used, they often fail to achieve satisfactory long-term patient outcomes and survival. Recently, immunotherapy has shown success in patients by harnessing important interactions between the immune system and cancer. However, many of these therapies lead to frequent side effects when administered systemically, prompting treatment modifications or discontinuation or, in severe cases, fatalities. New therapeutic approaches like intratumoral immunotherapy, characterized by reduced side effects, cost, and systemic toxicity, offer promising prospects for future applications in clinical oncology. In the context of locally advanced or metastatic cancer, combining diverse immunotherapeutic and other treatment strategies targeting multiple cancer hallmarks appears crucial. Such combination therapies hold promise for improving patient outcomes and survival and for promoting a sustained systemic response. This review aims to provide a current overview of immunotherapeutic approaches, specifically focusing on the intratumoral administration of drugs in patients with locally advanced and metastatic cancers. It also explores the integration of intratumoral administration with other modalities to maximize therapeutic response. Additionally, the review summarizes recent advances in intratumoral immunotherapy and discusses novel therapeutic approaches, outlining future directions in the field.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010292
003      
CZ-PrNML
005      
20250429135254.0
007      
ta
008      
250415e20250109sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2024.1479483 $2 doi
035    __
$a (PubMed)39850897
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Skalickova, Marketa $u BIOCEV, First Faculty of Medicine, Charles University, Vestec, Czechia $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czechia
245    10
$a Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer / $c M. Skalickova, K. Hadrava Vanova, O. Uher, J. Leischner Fialova, K. Petrlakova, M. Masarik, Z. Kejík, P. Martasek, K. Pacak, M. Jakubek
520    9_
$a Despite enormous progress, advanced cancers are still one of the most serious medical problems in current society. Although various agents and therapeutic strategies with anticancer activity are known and used, they often fail to achieve satisfactory long-term patient outcomes and survival. Recently, immunotherapy has shown success in patients by harnessing important interactions between the immune system and cancer. However, many of these therapies lead to frequent side effects when administered systemically, prompting treatment modifications or discontinuation or, in severe cases, fatalities. New therapeutic approaches like intratumoral immunotherapy, characterized by reduced side effects, cost, and systemic toxicity, offer promising prospects for future applications in clinical oncology. In the context of locally advanced or metastatic cancer, combining diverse immunotherapeutic and other treatment strategies targeting multiple cancer hallmarks appears crucial. Such combination therapies hold promise for improving patient outcomes and survival and for promoting a sustained systemic response. This review aims to provide a current overview of immunotherapeutic approaches, specifically focusing on the intratumoral administration of drugs in patients with locally advanced and metastatic cancers. It also explores the integration of intratumoral administration with other modalities to maximize therapeutic response. Additionally, the review summarizes recent advances in intratumoral immunotherapy and discusses novel therapeutic approaches, outlining future directions in the field.
650    _2
$a lidé $7 D006801
650    12
$a nádory $x terapie $x imunologie $7 D009369
650    12
$a imunoterapie $x metody $7 D007167
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a zvířata $7 D000818
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a nádorové mikroprostředí $x imunologie $7 D059016
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Hadrava Vanova, Katerina $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United States
700    1_
$a Uher, Ondrej $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United States
700    1_
$a Leischner Fialova, Jindriska $u BIOCEV, First Faculty of Medicine, Charles University, Vestec, Czechia $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czechia $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Petrlakova, Katerina $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Masarik, Michal $u BIOCEV, First Faculty of Medicine, Charles University, Vestec, Czechia $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czechia $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czechia $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Kejík, Zdeněk $u BIOCEV, First Faculty of Medicine, Charles University, Vestec, Czechia $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czechia
700    1_
$a Martasek, Pavel $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czechia
700    1_
$a Pacak, Karel $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United States
700    1_
$a Jakubek, Milan $u BIOCEV, First Faculty of Medicine, Charles University, Vestec, Czechia $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czechia
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 15 (20250109), s. 1479483
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39850897 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135250 $b ABA008
999    __
$a ok $b bmc $g 2311571 $s 1247373
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 15 $c - $d 1479483 $e 20250109 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
GRA    __
$a Z01 HD008735 $p Intramural NIH HHS $2 United States
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace